1. Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension.
- Author
-
Zhou, Yu-Ping, Wei, Yun-Peng, Yang, Yin-Jian, Xu, Xi-Qi, Wu, Tao, Liu, Chao, Mei, Ke-Yi, Peng, Fu-Hua, Wang, Hai-Ping, Sun, Kai, Li, Jing-Yi, Wang, Hui-Fang, Li, Meng-Tao, Wang, Duo-Lao, Miao, Qi, Jiang, Xin, and Jing, Zhi-Cheng
- Subjects
- *
TAKAYASU arteritis , *PULMONARY hypertension , *TRANSLUMINAL angioplasty , *POSITIVE pressure ventilation , *CHRONIC obstructive pulmonary disease , *GIANT cell arteritis , *PULMONARY hypertension treatment , *RETROSPECTIVE studies , *TREATMENT effectiveness , *ANGIOPLASTY , *LONGITUDINAL method , *DISEASE complications - Abstract
Background: Percutaneous transluminal pulmonary angioplasty (PTPA) is a treatment modality for chronic thromboembolic pulmonary hypertension, but whether it can be applied to Takayasu arteritis-associated pulmonary hypertension (TA-PH), another chronic obstructive pulmonary vascular disease, remains unclear.Objectives: This study sought to investigate the efficacy and safety of PTPA for TA-PH.Methods: Between January 1, 2016, and December 31, 2019, a total of 50 patients with TA-PH who completed the PTPA procedure (the PTPA group) and 21 patients who refused the PTPA procedure (the non-PTPA group) were prospectively enrolled in this cohort study. The primary outcome was all-cause mortality. The safety outcomes included PTPA procedure-related complications.Results: Baseline characteristics and medical therapies were similar between the PTPA group and the non-PTPA group. During a mean follow-up time of 37 ± 14 months, deaths occurred in 3 patients (6.0%) in the PTPA group and 6 patients (28.6%) in the non-PTPA group, contributing to the 3-year survival rate of 93.7% in the PTPA group and 76.2% in the non-PTPA group (P = 0.0096 for log-rank test). The Cox regression model showed that PTPA was associated with a significantly reduced hazard of all-cause mortality in TA-PH patients (HR: 0.18; 95% CI: 0.05-0.73; P = 0.017). No periprocedural death occurred. Severe complications requiring noninvasive positive pressure ventilation occurred in only 1 of 150 total sessions (0.7%).Conclusions: PTPA tended to be associated with a reduced risk of all-cause mortality with acceptable safety profiles and seemed to be a promising therapeutic option for TA-PH patients. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF